



Key Indices Update

Indices	Close	Change (%)
Nifty	24414.40	0.147
Sensex	80746.78	0.137
Midcap	54287.75	1.597
Smallcap	16417.95	1.387

Trend Strength Indicator

Nifty 50 Stocks above	NSE Advance /
200 EMA	Decline
31	1772/1049

Key Data

Data	Current	Previous
Dow Jones	41,210.50	40,265.5
U.S. Dollar Index	99.83	99.09
Brent Crude (USD/BBL)	61.30	65.58
US 10Y Bond Yield (%)	4.28	4.21
India 10Y Bond Yield (%)	6.33	6.37

Sectoral Data

Sector	Close	Change (%)
BANKNIFTY	54632.95	0.677
NIFTYAUTO	23070.25	1.467
NIFTYENERG	34076.45	0.907
NIFTYFINSR	27905.65	0.977
NIFTYFMCG	56515.85	لا 0.65
NIFTYIT	35931.00	0.177
NIFTYMEDIA	1521.50	0.907
NIFTYMETAL	8600.20	0.897
NIFTYPHARM	21461.80	0.34ك
NIFTYREALT	865.45	1.157

May 08, **2025**

Fundamental

Refer Page 02

Stock for Investment

Stock Name	Sector	*CMP (₹)	^TP (₹)	Upside
Reliance	Oil & Gas	1,406	1,563	11.2%

*CMP as on May 07 2025

Top News

- + Lupin Ltd. has announced the launch of Eslicarbazepine Acetate Tablets in the U.S. market in strengths of 200 mg, 400 mg, 600 mg, and 800 mg, following the approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). The company is eligible for 180-day shared generic exclusivity.
- + Kaynes Technology India Ltd. is set to acquire a 100% stake in August Electronics Inc. through a share purchase transaction valued at CAD 57 million.

Technical

Refer Page 03-04

- + Nifty remained volatile but managed to close slightly in the green amid mixed signals.
- + Geopolitical tensions, following **India's military response to a** terrorist attack, triggered a gap-down opening.
- + Sector-wise, the trend was mixed—auto, realty, and metal sectors posted gains, while pharma and FMCG ended in the red.
- + All eyes are now on the US Fed, and markets are likely to react to the FOMC meeting outcome and commentary in early trades.
- + On the index front, **Nifty is attempting to hold the 24,100 level**; a breach could lead to further **downside towards 23,800**.
- + Stock of the day TATASTEEL





Fundamental

Top **News**

01

Lupin Ltd. has announced the launch of Eslicarbazepine Acetate Tablets in the U.S. market in strengths of 200 mg, 400 mg, 600 mg, and 800 mg, following the approval of its Abbreviated New Drug Application (ANDA) by the U.S. Food and Drug Administration (FDA). The company is eligible for 180-day shared generic exclusivity.

02

Kaynes Technology India Ltd. is set to acquire a 100% stake in August Electronics Inc. through a share purchase transaction valued at CAD 57 million.

03

NLC India has formed a Joint Venture, NIRL Assam Renewables Limited, with Assam Power Distribution Company Limited (APDCL). NLC India Renewables Limited, a subsidiary of NLC India, holds a 51% stake. The JV aims to develop and implement green energy projects, supporting Assam's transition to sustainable power sources.

04

Nazara Technologies Ltd's Resolution Plan for acquiring Smaaash Entertainment Private Limited has been approved by the National Company Law Tribunal (NCLT), Mumbai.

05

Coal India Ltd reported a 12% year-on-year rise in Q4 net profit to ₹9,604 crore, despite a 1% drop in revenue to ₹37,825 crore. EBITDA grew 3.5% to ₹11,790 crore, with margins improving to 31.2%.

Stock for Investment

Reliance Industries Ltd

Stock Symbol	Reliance
Sector	Oil & Gas
*CMP (₹)	1,406
^Target Price	1,563
Upside	11.2%
*CMP as on MaY 07, 2025	

- + Reliance Industries Limited (RIL) is one of India's largest conglomerates, with operations spanning petrochemicals, refining, oil & gas, retail, and telecommunications.
- + RIL reported consolidated net revenue of ₹2,64,573 crore for Q4FY25, up 9.9% YoY and 8.5% QoQ, supported by broad-based recovery across most segments. EBITDA margins remained stable, and PAT rose 6.1% YoY to ₹22,434 crore, aided by improved cost efficiencies.
- + Jio's ARPU grew 1.4% QoQ and 13.5% YoY, with 6.1 million net customer additions and EBITDA margins near 50%. Reliance Retail's revenue increased 16.3% YoY, driven by productivity, customer engagement, and the addition of 238 new stores.
- + The media business, led by JioStar, is emerging as a growth pillar, while O2C revenue declined 10% YoY but improved 5% QoQ with resilient margins. The New Energy segment is gaining traction, highlighted by a 1GW solar module facility and aggressive investments in clean energy technologies.
- + Based on these assumptions, **Reliance's revenue/EBITDA** is expected to grow at a CAGR of 10%/15.1% over FY25-27E, driven by strong retail, digital, and new energy momentum. Maintain BUY rating with a target price of ₹1,563.

^{&#}x27;Time horizon - upto 11 Months





Technical

Volatility to stay. Maintain cautious stance and avoid aggressive bets.

NIFTY	S1	\$2	R1	R2
24414.40 7 34.80 (0.14%)	24250	24100	24500	24600



- Nifty remained volatile but managed to close slightly in the green amid mixed signals.
- + Geopolitical tensions, following **India's** military response to a terrorist attack, triggered a gap-down opening.
- + Sector-wise, the trend was mixed—auto, realty, and metal sectors posted gains, while pharma and FMCG ended in the red.
- On the index front, Nifty is attempting to hold the 24,100 level; a breach could lead to further downside towards 23,800.

BANKNIFTY	S1	S2	R1	R2
54610.90 7 339.50 (0.63%)	54200	53900	55000	55400



- + The banking index recovered from its previous session's losses, gaining 0.63%.
- Most of the major banks saw positive gains, with private banking giants leading the charge, although PNB and IndusInd Bank witnessed profit booking.
- + The index bounced back from the support level of its consolidation breakout, limiting further profit-taking.
- + Maintaining above this level is critical for the uptrend to remain continue.
- + In terms of levels, support will remain at 54,200-53,900, while the immediate resistance on the upside is at 55,000-55,400.





Technical

Stock of the day	Recom.	CMP (₹)	Range*	SL	Target
TATASTEEL	BUY	146	144-146	141	153



- + After experiencing significant correction from its recent swing high, the stock found support by forming a double bottom formation.
- + It has formed a strong base near its medium to long term moving average creating a fresh pivot.
- + The volumes have been robust during this rebound suggesting buying interest from lower levels.
- + We expect this recovery to strengthen further and hence longs can be created in the mentioned range.

Stocks	Name	Price	Price %
	WELSPUNLIV	136.20	13.047
m St	CCL	773.00	11.317
Momentum 9 Midcap	KPRMILL	1107.00	8.637
ome	HUDCO	214.00	וב 1.81
Σ	SUVENPHAR	1088.80	2.77צ

Name	Price	Price %	_
NIFTYAUTO	23070.25	1.467	Rang Br
NIFTYREALT	865.45	1.157	<u>ө</u>
NIFTYFINSR	27905.65	0.977	Break ikdow
NIFTYPHARM	21461.80	0.34ע) Out
NIFTYFMCG	56515.85	لا 0.65	

K S	Name	Price	Price %
Gainers	PEL	1039.15	7.937
	IIFL	370.00	7.457
F&O	PAYTM	873.40	7.197
വ	BSE	6670.00	6.817
Тор	AARTIIND	458.50	5.337

Name	Price	Price %	Top
ASIANPAINT	2322.00	וע 3.97	์ บ
ADANIENSOL	875.20	3.55ك	F&O
CHAMBLFERT	708.00	2.57كا	
SUNPHARMA	1780.90	2.10 🗵	Losers
HUDCO	214.00	בו8.1	Ľ

	Name	Price	Price %
Bullish Charts	BSE	6670.00	6.817
	KEI	3296.10	3.207
	MOTHERSON	142.50	5.197
	MRF	140610.00	4.167
	SRF	3050.80	4.197

Name	Price	Price %	
BAJAJ-AUTO	7845.00	لا1.26	
HUDCO	214.00	I.81Z	
INDIANB	558.00	עו6.0	
PATANJALI	1827.00	וב 1.28	
SUNPHARMA	1780.90	ב2.10	

4





Research Team

Name	Email ID
Ajit Mishra	ajit.mishra@religare.com
Abhijeet Banerjee	abhijeet.banerjee@religare.com
Gaurav Sharma	gauravsharma2@religare.com
Ashwani Harit	ashwani.harit@religare.com
Divya Parmar	divya.parmar@religare.com
Vinay Kalani	vinay.kalani1@religare.com
Rajan Gupta	rajan.gupta1@religare.com





Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: https://www.religareonline.com/disclaimer

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation—Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement		Answer	
		Yes	No	
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No	
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No	
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No	
	I/we have received any compensation from the subject company in the past twelve months?		No	
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No	
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No	
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No	
	I/we have served as an officer, director or employee of the subject company?		No	
	I/we have been engaged in market making activity for the subject company?		No	

Nature of Interest if answer to F(a) above is Yes:	Name(s) with Signature(s) of RA(s)

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results